Treatment Approach Analysis of Hospitalized Patients with Liver Cirrhosis; A Prospective Observational Study
Pharmaceutical Science-Pharmacy practice
DOI:
https://doi.org/10.22376/ijpbs/lpr.2022.12.6.P70-76Keywords:
Treatment approach analysis, Liver cirrhosis, Drug-drug interaction, and Hepatic dose adjustmentAbstract
The analysis of medications prescribed for managing patients with liver cirrhosis provide essential insight into appropriate therapeutic regimens and prevents inappropriate therapeutic outcomes. This study aimed to analyze the treatment approach of hospitalized patients with liver cirrhosis and identify drug-drug interactions (DDIs) and hepatic dose adjustment associated with treatment. A prospective observational study was conducted for 12 months in the Medicine Department of Bharati Hospital and Research Center, located in Pune, India. Medication charts of 113 patients who were diagnosed with cirrhosis were reviewed. Pharmaceutical care-related standard tools were applied to identify DDIs and medications requiring hepatic dose adjustment. Investigating the number of complications showed that ascites (40.7%) were the most common complication associated with liver cirrhosis. The treatment approach analysis revealed that antibiotics (23.6%), diuretics (22.5%), and analgesics (13.8%) were the most frequently prescribed pharmacological class of medications. The most commonly identified DDIs was an interaction between Mefenamic Acid-Furosemide (46.3%). In addition, approximately half of prescribed Paracetamol (48.1%) required its dose to be adjusted according to the patient's liver function test. Therefore, periodic analysis of prescribed medications needs to be performed since the inappropriate selection of medications can further lead to drug-related problems like DDIs or hepatic dose adjustment. Our findings provide feedback to prescribers to improve the appropriate selection of medications and enhance patient safety.
References
Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371(9615):838-51. doi: 10.1016/S0140-6736(08)60383-9.
Lozano R, Naghavi Mohsen, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095-128. doi: 10.1016/S0140-6736(12)61728-0, PMID 23245604.
Lucena MI, Andrade RJ, Tognoni G, Hidalgo R, De La Cuesta FS, Spanish Collaborative Study Group On Therapeutic Management In Liver Disease. Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. Eur J Clin Pharmacol. 2002;58(6):435-40. doi: 10.1007/s00228-002-0474-1. PMID 12242604.
Weersink RA, Bouma M, Burger DM, Drenth JPH, Hunfeld NGM, Kranenborg Minke, et al. Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion. BMJ Open. 2016;6(10):e012991. doi: 10.1136/bmjopen-2016-012991, PMID 27733414.
Amarapurkar DN. Prescribing medications in patients with decompensated liver cirrhosis. Int J Hepatol. 2011;2011:519526. doi: 10.4061/2011/519526. PMID 21994861.
David S, Hamilton JP. Drug-induced liver injury. U.S. Gastroenterol Hepatol Rev. 2010;6:73-80. PMID 21874146.
Mohammed BabaS, Aidoo M. Drug treatment of patients with liver cirrhosis in a tertiary hospital in Northern Ghana: does it comply with recommended guidelines? Int J Hepatol. 2020;2020:9750194. doi: 10.1155/2020/9750194. eCollection 2020. PMID 32550025.
Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1-85. PMID 4950264.
Lexicomp. Lexicomp clinical drug information [cited Dec 1 2019]. Available from: https://online.lexi.com/lco/action/login.
Guy J, Peters MG. Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes. Gastroenterol Hepatol (N Y). 2013;9(10):633-9. PMID 24764777.
Roerecke M, Vafaei A, Hasan OSM, Chrystoja BR, Cruz M, Lee R, et al. Alcohol consumption and risk of liver cirrhosis: A systematic review and meta-analysis. Am J Gastroenterol. 2019;114(10):1574-86. doi: 10.14309/ajg.0000000000000340, PMID 31464740.
Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: evidence based treatment. World J Gastroenterol. 2014;20(18):5442-60. doi: 10.3748/wjg.v20.i18.5442, PMID 24833875.
Bilal F, Arain MI, Dayo A, Ghoto MA, Bilal F. Evaluation of drug utilization and prevalence of cirrhotic patients by using WHO prescribing indicators at tertiary care hospital. Isra Medicine [journal]. 2019;11(4):300-4.
Dumatar CB, Malpure RA. Study of prescribing patterns for prophylaxis and treatment of complications of liver cirrhosis in hospitalised patients at a tertiary care teaching hospital. Natl J Integr Res Med. 2017;8(3):98-104.
Fogel MR, Sawhney VK, Neal EA, Miller RG, Knauer CM, Gregory PB. Diuresis in the ascitic patient: a randomized controlled trial of three regimens. J Clin Gastroenterol. 1981;3(1);Suppl 1:73-80. doi: 10.1097/00004836-198100031-00016, PMID 7035545.
Biggins SW, Angeli P, Garcia-Tsao G, Pere, Ginès P, Ling SC, Nadim MK et al., Simon C Ling, Mitra K Nadim, et al Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-48. doi: 10.1002/hep.31884, PMID 33942342.
Felisart J, Rimola A, Arroyo V, Perez-Ayuso RM, Quintero E, Gines P, et al. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology. 1985;5(3):457-62. doi: 10.1002/hep.1840050319, PMID 3888810.
Dwyer JP, Jayasekera C, Nicoll A. Analgesia for the cirrhotic patient: a literature review and recommendations. J Gastroenterol Hepatol. 2014;29(7):1356-60. doi: 10.1111/jgh.12560, PMID 24548074.
Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis - a practical guide. Aliment Pharmacol Ther. 2013;37(12):1132-56. doi: 10.1111/apt.12324. PMID 23638982.
Ge PS, Runyon BA. Preventing future infections in cirrhosis: a battle cry for stewardship. Clin Gastroenterol Hepatol. 2015;13(4):760-2. doi: 10.1016/j.cgh.2014.10.025. PMID 25460013.
Franz CC, Egger S, Born C, Rätz Bravo AE, Krähenbühl S. Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis. Eur J Clin Pharmacol. 2012;68(2):179-88. doi: 10.1007/s00228-011-1105-5. PMID 21842337.
Aghili M, Neelathahalli Kasturirangan MN. Identifying characteristics of drug-related problems in critically ill patients with decompensated liver cirrhosis. Eur J Gastroenterol Hepatol. 2019;31(12):1569-76. doi: 10.1097/MEG.0000000000001492, PMID 31464786.
Arroyo V, Ginés P, Rimola A, Gaya J. Renal function abnormalities, prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites. An overview with emphasis on pathogenesis. Am J Med. 1986;81(2B):104-22. doi: 10.1016/0002-9343(86)90912-5, PMID 2944381.
Manias E, Williams A, Liew D. Interventions to reduce medication errors in adult intensive care: a systematic review. Br J Clin Pharmacol. 2012;74(3):411-23. doi: 10.1111/j.1365-2125.2012.04220.x, PMID 22348303.
Cano FG, Rozenfeld S. Adverse drug events in hospitals: a systematic review. Cad Saude Publica. 2009;25(3);Suppl 3:S360-72. doi: 10.1590/s0102-311x2009001500003, PMID 20027385.
Periáñez-Párraga L, Martínez-López I, Ventayol-Bosch P, Puigventós-Latorre F, Delgado-Sánchez O. Drug dosage recommendations in patients with chronic liver disease. Rev Esp Enferm Dig. 2012;104(4):165-84. doi: 10.4321/s1130-01082012000400002, PMID 22537365.
Published
How to Cite
Issue
Section
Copyright (c) 2022 Azardokht Karimi Mir, Atmaram P. Pawar, Bijoy Kumar Panda
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
